Ann: Investor Update-STL.AX, page-49

First 49 Last

Share
Profile

Follow
Rajenp5

2,391 Posts.

19

23/10/16

17:16

Post #: 20061119
Share

Originally posted by Zman28 ↑

@Kepo

In the preliminary report the Board had booked approx 25% of the deferred tax assets from the carry forward income tax losses and capital losses which were acquired as part of the reverse takeover of ICP back in August 2015 and which in fact are >$25mil worth of tax losses with a actual tax benefit of >$8mil.

This was a conservative view taken by the Board at the time of the preliminary report.

The auditors request this be backed out given the underlying loss and history of losses in ICP and suggested that in fact the booking of this deferred tax asset should be made at this year's half year accounts or in the FY17 accounts now that we are profitable and cashflow positive etc...

We agreed with the auditors and hence made that change and a note on the total tax deferred asset that is likely to be booked in the future is noted in Note 10C of the accounts. The tax deferred asset that can be booked can only be in relation to the income tax losses and not the capital losses carried forward by ICP.

So in short, some time before we pay tax, so the dividend to be paid in 2017 will have franking credits attached but future dividends once the franking credits available are used up will be unfranked.

Expand

Thanks Zman for taking the trouble. You set the Gold standard in the ASX in addressing our concerns and queries. I'll be buying more come Monday. Might wait till the end of trading though as whoevers selling likes to blindside investors

STL Price at posting: 3.4¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SMI

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Good habits matters when it comes to finances

PR1

Fourfold skarn increase points the way to viable garnet project, says Pure

NOX

Noxopharm aims for autoimmune market with first human trial of SOF-SKN